Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Journey Medical Corporation Reports Combined Emrosi Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
